Viatris Agrees to Settle EpiPen Antitrust Litigation for $264 Million
The proposed settlement, which requires a judge’s approval, would resolve a legal battle that began after the company, in 2016, raised the price for two EpiPens to $608 from $100.
View original article
Contributor: Jesus Jiménez
